CLINICAL AND THERAPEUTIC IMPLICATIONS OF SPROUTY2 FEEDBACK DYSREGULATION IN BRAF V600E MUTATION POSITIVE PAPILLARY THYROID CANCER

BACKGROUND: The BRAF V600E (BRAF+) mutation activates the MAPK/ERK pathway and may confer an aggressive phenotype in papillary thyroid cancer (PTC). However, clinically BRAF+PTC behavior varies from indolent to aggressive. SPRY2 is a negative feedback regulator of the MAPK/ERK pathway. We hypothesiz...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dultz, Linda A., Dhar, Shumon, Ogilvie, Jennifer B., Heller, Keith S., Bar-Sagi, Dafna, Patel, Kepal N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4100696/
https://ncbi.nlm.nih.gov/pubmed/24094449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2013.06.024
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak